Conference Coverage
Latest News
Jan 12, 2026 | News
Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1
Published Phase 2 Data Highlight Potential of NNZ-2591 in Phelan-McDermid Syndrome
Jan 12, 2026
Neuroprotective Agent Privosegtor Gains FDA Breakthrough Designation for Optic Neuritis
Jan 12, 2026
This Week on NeurologyLive® — January 12, 2026
Jan 12, 2026
Annexon Submits Marketing Authorization Application for Tanruprubart to Treat Guillain-Barré Syndrome
Jan 11, 2026
Advertisement
Shorts
1:03
Key Updates Proposed for Revised NMOSD Diagnostic Criteria
12 hours ago
by
Shailee Samir Shah, MD(+1 more)
1:03
Phase 2 Data of Vidofludimus Calcium in Progressive MS
5 days ago
by
Robert Fox, MD(+1 more)
1:22
Strategies for Increasing Diversity in Brain Aging Research
7 days ago
by
Charisse Winston-Gray, PhD, MSc(+1 more)
1:20
Media-Driven Misconceptions of Narcolepsy
a month ago
by
Julie Flygare, JD(+1 more)
0:30
Barriers to Early Diagnosis and Access to Care in MS
2 months ago
by
Ethel Ciampi, MD, MSc(+1 more)
1:30
Collaboration Within the ALS Community
2 months ago
by
Jinsy A. Andrews, MD, MSc(+1 more)
1:30
Safety Considerations for Kygevvi in Tk2d
2 months ago
by
Fabian Somers, PhD(+1 more)
1:30
Data Backing First Treatment for Tk2d
2 months ago
by
Fabian Somers, PhD(+1 more)
1:30
Training the Next Neuromuscular Specialists
2 months ago
by
John Norbury, MD(+1 more)
1:15
Evolving Landscape of Myasthenia Gravis Treatment
2 months ago
by
Leila Darki, MD(+1 more)
Coverage of AANEM 2025
Get direct access to interviews with experts, straight from the conference floor in San Francisco, as well as the latest data and clinical news updates.
Mind Moments Podcast
Mind Moments® is a biweekly podcast from NeurologyLive that brings you exclusive interviews with expert neurologists and clinicians.
DAMM Good Sleep
Check out DAMM Good Sleep × NeurologyLive for neurology-focused sleep content to allow any neurology stakeholder to use sleep as the diagnostic, prognostic, and therapeutic neurology tool it should be.
NeuroVoices
NeuroVoices is NeurologyLive's series of in-depth, exclusive Q&A conversations with a variety of experts in the care and management of patients with neurologic diseases about topics in clinical care and therapeutic development.
Gold Standard Centers
Gold Standard Centers is our deep dive feature series on examples of institutional success in neurologic medicine, highlighting the centers that are leading the way in care.
Videos
Podcasts
Continuing Medical Education
Advertisement
All News
Advertisement
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on epilepsy comorbidities!
Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, provided an outlook on the 2026 MDA meeting and what clinicians should look forward to in preparation.
A review of clinical trial and real-world data found no evidence that oral anticoagulants increase brain imaging abnormalities in patients treated with lecanemab or donanemab for early Alzheimer disease.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 9, 2026.
Review upcoming clinical trials with data readouts expected in the first half of 2026, providing updates relevant to ongoing research and clinical practice in neurology.
Bright Mind Biosciences reveals promising results for BMB-101 in treating drug-resistant seizures, paving the way for future clinical trials.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Johannes Streffer, MD. [LISTEN TIME: 14 minutes]
In a pilot study, liraglutide, a drug used for diabetes and weight-loss, significantly reduced headache days in patients with obesity and chronic or high-frequency migraine, suggesting a potential new preventive therapy.
A recent analysis reveals fenfluramine's positive effects on executive functioning in adults with Lennox-Gastaut syndrome, independent of seizure reduction.
Follow NeurologyLive's conference journey in 2026, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.
Advertisement
Fenfluramine shows significant seizure reduction in CDKL5 deficiency disorder, offering hope for families facing treatment-resistant epilepsy challenges.
A pair of pediatric epileptologists highlight the systemic and patient level factors driving inequities in infantile epileptic spasms syndrome care and outline paths toward more equitable diagnosis and treatment.
Final safety data from an open-label study presented at AES 2025 supported long-term fenfluramine use in pediatric and adult patients with Dravet syndrome or Lennox-Gastaut syndrome.
An AES study revealed the real-world persistence of fenfluramine in treating Lennox-Gastaut syndrome, highlighting patient demographics and treatment trends.
A recent trial reveals semaglutide's potential for neurological improvement in stroke patients, despite no overall functional recovery benefits.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Key Neurology Trial Readouts to Watch in Early 2026
2
BMB-101 Heads for Registrational Trials Following Positive Phase 2 Data in Absence Seizures, Developmental Encephalopathies
3
Neuroprotective Agent Privosegtor Gains FDA Breakthrough Designation for Optic Neuritis
4
Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1
5